A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Last updated:
2026-08-01
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE EFFECT OF INCLISIRAN ON PREVENTING MAJOR ADVERSE CARDIOVASCULAR EVENTS IN HIGH-RISK PRIMARY PREVENTION PATIENTS (VICTORION-1 PREVENT)

Intervention/treatment:
INCLISIRAN (KJX839)
Medical condition:
CARDIOVASCULAR DISEASE
Protocol code:
CKJX839D12302
Control number:
271410
Status:
Active, not recruiting
Approved:
March 01, 2023
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT05739383
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
40 Years to 79 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Sponsor
NOVARTIS PHARMACEUTICALS CANADA INC

Locations

Alberta

Novartis Investigative Site
Calgary, Alberta, T2H 2G4
Novartis Investigative Site
Edmonton, Alberta, T6K 4C1

British Columbia

Novartis Investigative Site
Kelowna, British Columbia, V1Y 3J8
Novartis Investigative Site
Vancouver, British Columbia, V6Z 1Y6

New Brunswick

Novartis Investigative Site
Moncton, New Brunswick, E1G 1A7

Nova Scotia

Novartis Investigative Site
Halifax, Nova Scotia, B3H 2Y9
Novartis Investigative Site
Halifax, Nova Scotia, B3H 4K4
Novartis Investigative Site
New Minas, Nova Scotia, B4N 3R7

Ontario

Novartis Investigative Site
Barrie, Ontario, L4N 7L3
Novartis Investigative Site
Brampton, Ontario, L6S 0C6
Novartis Investigative Site
Etobicoke, Ontario, M9R 4E1
Novartis Investigative Site
Guelph, Ontario, N1H 1B1
Novartis Investigative Site
Hamilton, Ontario, L8L 5G4
Novartis Investigative Site
London, Ontario, N6A 5W9
Novartis Investigative Site
Napean, Ontario, K2J 0V2
Novartis Investigative Site
Newmarket, Ontario, L3Y 2P6
Novartis Investigative Site
North York, Ontario, M6B 3H7
Novartis Investigative Site
Oshawa, Ontario, L1J 2K9
Novartis Investigative Site
Scarborough Village, Ontario, M1B 5N1
Novartis Investigative Site
Thornhill, Ontario, L4J 8L7
Novartis Investigative Site
Toronto, Ontario, M4G 3E8

Quebec

Novartis Investigative Site
Lévis, Quebec, G6W 5M6
Novartis Investigative Site
Mirabel, Quebec, J7J 2K8
Novartis Investigative Site
Montreal, Quebec, H4A 3J1
Novartis Investigative Site
Québec, Quebec, G1V 4G5
Novartis Investigative Site
Québec, Quebec, G2J 0C4
Novartis Investigative Site
Terrebonne, Quebec, J6X 4P7
Novartis Investigative Site
Trois-Rivières, Quebec, G9A 4P3
Novartis Investigative Site
Victoriaville, Quebec, G6P 3Z8
Did you find what you were looking for?